CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

Barchart · 2d ago

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases

CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.